PRFX vs. PBM, TRVN, ERNA, ONCT, ATNF, KRBP, ASLN, CWBR, ADXS, and EVFM
Should you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Psyence Biomedical (PBM), Trevena (TRVN), Eterna Therapeutics (ERNA), Oncternal Therapeutics (ONCT), 180 Life Sciences (ATNF), Kiromic BioPharma (KRBP), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Ayala Pharmaceuticals (ADXS), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry.
PainReform vs.
PainReform (NASDAQ:PRFX) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
PainReform received 3 more outperform votes than Psyence Biomedical when rated by MarketBeat users.
PainReform presently has a consensus price target of $8.00, indicating a potential upside of 163.59%. Given PainReform's stronger consensus rating and higher probable upside, equities analysts clearly believe PainReform is more favorable than Psyence Biomedical.
Psyence Biomedical's return on equity of 0.00% beat PainReform's return on equity.
37.3% of PainReform shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
PainReform has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500.
In the previous week, Psyence Biomedical had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for PainReform. Psyence Biomedical's average media sentiment score of 0.50 beat PainReform's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.
Summary
PainReform beats Psyence Biomedical on 6 of the 11 factors compared between the two stocks.
Get PainReform News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PainReform Competitors List
Related Companies and Tools
This page (NASDAQ:PRFX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PRFX Stock Alerts